Atabak Mokari Sells Shares of Corcept Therapeutics Incorporated $CORT
Key Points
- Atabak Mokari sold 40,000 shares of Corcept Therapeutics Incorporated ($CORT) worth $3.25 million.
- $CORT last traded around $81.75.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Atabak Mokari, Chief Financial Officer at Corcept Therapeutics Incorporated ($CORT), sold 40,000 shares at an average price of $81.15, for a total transaction of $3.25 million. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Corcept Therapeutics Incorporated Stock Down 28.2%
Shares of Corcept Therapeutics Incorporated ($CORT) traded around $81.75 on Wednesday, down 28.2% for the day.
Corcept Therapeutics Incorporated Earnings
Analysts Set New Price Targets
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Get Corcept Therapeutics Incorporated alerts
New 13F filings, insider trades, and analyst moves on $CORT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.